It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Tailored in vivo oncology studies delivering translational insights and high-quality data, empowering faster, smarter decisions through expert collaboration and proven scientific and drug discovery expertise.
As oncology continues to pose one of the greatest challenges to human health, advancing your pipeline requires data you can trust and a partner who understands the science behind it.
Our in vivo oncology scientists bring over 20 years drug discovery experience to every project, offering customized pharmacology services to meet your specific goals.
We work closely with you to design, implement, and execute studies that deliver robust preclinical data packages. These include pharmacodynamic, pharmacokinetic, and efficacy models, supported by biomarker analysis and expert interpretation accelerating decision-making and driving progress.
in vivo Oncology Model Expertise
Our capabilities combine deep scientific and drug discovery knowledge with high quality technical execution. Every preclinical study is built around your target biology and modality, integrating efficacy, PK/PD and biomarker data to generate insights that drive robust decision making and accelerate project progression.
Preclinical Tumor Models
Human cell line derived xenograft, syngeneic, orthotopic and humanized models.
Bespoke Model Development
Models built to reflect your target biology.
Tumor & Normal Tissue Biomarker Discovery
Access to ex vivo platforms for gene, protein and soluble analyte analysis, including whole-cell and immune cell profiling via flow cytometry.
Bioluminescent & Fluorescent Imaging
Tumor models and bioconstructs.
Radiotherapy Xstrahl CIX3 Platform:
Delivery of targeted tumor and whole-body radiation
Key Benefits
Oncology expertise
Work with a dedicated team of oncology specialists, 50% of whom are pharma-trained, with a strong track record of delivering clinical candidates.
Tailored design
Every study is built around your therapeutic’s biology and modality, creating a customized path to robust, decision-driving data.
Integrated insights
Combine in vivo efficacy with detailed tumor and tissue profiling to uncover PK/PD relationships, biomarker signals, and translational understanding all in one connected workflow.
Design Your Study for Success
We tailor study designs to address key considerations such as therapeutic PK and tolerability, target engagement and pathway biomarker analysis, schedule optimization, combination therapies, dose/efficacy (monotherapy and combination therapy) and dose/schedule optimization.
Why Choose Sygnature Discovery for in vivo Oncology Support ?
Expertise Across Modalities Small molecules, large molecules, DNA/RNA therapeutics, ADCs, viral and cell therapies, and radiotherapy.
Expert Consultation Our oncology leaders offer strategic input on study design and data interpretation, backed by over 20 years drug discovery experience.
Whether you need consultancy, embedded support, or fee-for-service collaboration, we adapt to your needs. Our experience in disease models and drug discovery amplifies the potential of every project we engage with.
Radiotherapy is a key treatment for various cancers often in combination with other therapies. In…
Posters
Related Solutions
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
Integrated solid form and formulation strategies reduce risk, improve stability and solubility, and accelerate progression from candidate selection to clinic.
Validated in vivo models deliver clinically relevant data across therapeutic areas, accelerating confident decisions and reducing risk in drug development.
Yes, we have the capabilities to conduct ex vivo analysis across a range of tumor and normal tissue. Our ex vivo platforms enable analysis at the gene and protein level.
Yes, Sygnature offers integrated drug discovery and has in-house bioanalysis capabilities.
Yes. We have a bank of Sygnature owned STR profiled and QC tested cell lines, however we understand there may be a need or preference to work with your own cell line, which we are happy to support.
An error has occurred, please try again later.An error has occurred, please try again later.
You're in the right place!
Peak Proteins has now fully integrated with Sygnature Discovery.
